Glargine PowerPoint PPT Presentations

Caracter sticas ideales de una Insulina de acci n prolongada ... Diabetes mellitus tipo 1. Insulina Glargina: control gluc mico. Hb A1C inicial. Hb A1C final ...

Biphasic insulin aspart 30 + metformin vs once-daily insulin glargine + glimepiride A study in people with type 2 diabetes Kann P, Regulski M, Medding J, Ligthelm R

... non-glargine insuline 10 106 ? 2,286 UK 6 22 447 Scotland 25 149 5,970 Sweden Not studied 669 23,855 Germany Breast cancer All cancer Exposed No data on ...

His insulin dose is 60 units of insulin glargine twice daily and premeal insulin lispro 40-50 units before meals.

... efficacy and safety of exenatide twice daily or mealtime insulin lispro in patients inadequately controlled by insulin glargine and metformin despite up ...

Comparison of PZI, porcine lente, glargine in healthy ... U-40 insulin, porcine origin ... Received either PZI, porcine lente, glargine (0.25 or 0.5 U/kg BID) ...

Initiating Insulin Therapy in Type 2 Diabetes DIABETES CARE, Feb. 2005 Raskin Philip for the INITIATE study group The INITIATE study: NovoMix 30 (BID) vs glargine ...

US FDA Center for Drug Evaluation and Research. ... The hypoglycaemia data confirm that insulin glargine is better suited to this ...

Diabetes, Obesity and Cancer Is Hyperinsulinemia a Culprit? Emily Jane Gallagher Mount Sinai Medical Center New York, NY Insulin Glargine [GlyA21] insulin M1 Bio ...

superior prandial insulin replacement. Less hypoglycemia ... It is easier to add basal insulin than to teach Pts to adjust prandial dose. Glargine ...

Get a sample brochure@ http://tinyurl.com/hlw3qpn In the Global Insulin Market, Biocon Company has launched their product in Japan called insulin glargine. It is a basal biosimilar insulin glargine which is pre-filled pen with 3 ml of 100 IU insulin glargine which is ready to use. It is affordable as well as world class drug. In the upcoming years, there is going to be high demand for biosynthetic human insulin compared to other alternatives. North America is the leading region in the Global Insulin Market due to the increasing population which is increasingly getting diabetes or other insulin related diseases. Europe is expected to have high demand for insulin injection and insulin pump for elderly population in upcoming years.

Basal Insulin: NPH or Glargine Provides insulin needed to prevent fasting and pre-meal hyperglycemia MUST always be used if type 1 diabetes!!!

... especially on mornings after taking her insulin if she had not eaten. ... Her Insulin Glargine was increased from 45 to 50 units and her Insulin Aspart ...

Biosimilar is a biological product which is similar to the reference product, already approved by authorities and marketed by companies other than the patent holder company. Insulin is a hormone produced by pancreatic cell which is responsible for absorption of glucose from the blood. Lack of insulin in the body causes diabetes. Insulin is available in different forms depending upon the sources such as animal derived, chemically synthesized or produced through recombinant technology. Insulin can be categorized as fast acting, immediate acting and long acting depending upon the absorption of insulin from the blood in the body. Glargine and lispro are two types of insulin.

Insulin degludec (Tresiba ) ULTRA-LONG ACTING BASAL INSULIN * Andre McMahon PharmD Candidate, University of Florida College of Pharmacy Overview Approval status ...

Describe the pharmacokinetics and pharmacodynamics of human and analog insulins ... 1997;349:97-51. White JR, et al. Postgrad Med. 1997;101:58-70. ...

The premixed insulin analogue Updated January 2006 Version 2006.1 Contents NovoMix 30 the premixed insulin analogue Formulation and proof of concept Benefits ...

Title: PowerPoint Presentation Author: Iv n Last modified by: Rafa Created Date: 1/1/1601 12:00:00 AM Document presentation format: Presentaci n en pantalla

Title: PowerPoint Presentation Author: user Last modified by: Claudia Created Date: 12/28/2004 8:02:31 PM Document presentation format: On-screen Show

Fasting Blood/Plasma Glucose (FBG/FPG) Post Prandial Blood Glucose ... Fasting Plasma Glucose. Taken in the morning. Was basal adequate? Diabetes Metrics A1C ...

Title: PowerPoint Presentation Author: Curtis Kapsner Last modified by: Windows User Created Date: 10/4/2005 9:30:42 AM Document presentation format

Bruce W. Bode, MD, FACE. Atlanta Diabetes Associates. Atlanta, Georgia ... Bode, et al. Diabetes 52,(Suppl 1), 2003 Abstract 438. ...

Practical Considerations in Clinical Management

Prevalence of Diabetes in the US Goals of Intensive Diabetes Management Near-normal glycemia HbA1c less than 6.5 to 7.0% Avoid short-term crisis Hypoglycemia ...

Matthew C. Riddle, Geremia B. Bolli, Monika Ziemen, Isabel Muehlen-Bartmer, Florence Bizet, and Philip D. Home, on behalf of the EDITION 1 Study Investigators

Guillermo E. Umpierrez, M.D., Roma Gianchandani, M.D., Dawn Smiley, M.D., Sol Jacobs, M.D., David H. Wesorick, M.D., Christopher Newton, M.D., Farnoosh Farrokhi, M.D ...

Mrs. G, 46 y.o. was diagnosed with Type 2 DM diagnosed 5 years ago (initially ... BP is 126/72, micro-albumin is 9 on lisinopril 10 mg, LDL is 89 on Lipitor 10 mg. ...

Pharmacoeconomics 101 2005 DoD Pharmacoeconomics & Pharmacy Benefits Conference 11 January LtCol David Bennett, Capt Jill Dacus, Eugene Moore, PharmD

crane. whiting. yale. smith. haste. barton. sparke. ferguson. ... mitchell. davey. fayers. see 2/12. write gp. parsons. horridge. ... max. min. m/f. age at start. bmi ...

Title: DIABETES Author: dboles Last modified by: Cory True Created Date: 4/24/2006 11:38:09 AM Document presentation format: On-screen Show (4:3) Company

Title: PowerPoint Presentation Author: Al Humayyd Last modified by: xp Created Date: 1/19/2003 5:37:34 PM Document presentation format: (3 ...

To compare the efficacy of a basal-bolus insulin protocol consisting of ... Corticosteroid therapy. ICU stay. Sliding Scale Insulin (n=65) www.dave.md. RABBIT 2 ...

Advantages and disadvantages of observational and experimental studies for diabetes research Sarah Wild, University of Edinburgh BIRO Academy 2nd Residential Course

Randomised, double-blind, single dose crossover, euglycaemic clamp2. NovoMix 30: ... Design Randomised, open-labelled, three-period crossover trial ...

Brugen af glukose-s nkende medicin og risikoen for at udvikle cancer: relation til behandlings-l ngde og kumuleret dosis Charlotte Andersson, stud. med.

Dans le monde, plus de 200 millions de personnes sont atteintes de diab te ... Peut aggraver l'ob sit - en cas de diab te de type 2. Emp che les personnes atteintes de ...

PETS Therapy. Step--Spelled Backwards. All at once, nothing first, ... Leuven: Intensive Insulin Therapy in Critically Ill Patients ...

Therapeutic Options Insulins

Use of Insulin in treatment of diabetes mellitus Prof. Hanan Hagar NPH, is a Neutral Protamine Hagedorn insulin in phosphate buffer. a combination of protamine ...

About 50% should be given as prandial therapy. Replacement therapy. Supplement: ... Pre-prandial levels (by increasing bolus insulin or changing to rapid acting) ...

Basal/Bolus Concept. In healthy patients, pancreas secretes large amounts ... Also referred to as bolus or mealtime insulin, usually administered before eating ...

Basal-Bolus, Insulin Pumps, Carbohydrate Counting, Combination Therapy Dr.Ihab Tadros Medical Director Daisy Care Medical USA The Leader in insulin Pump Therapy

Effective Glycemic Control Outside of the Critical Care Unit Christopher A. Newton, MD, FACE canewto@emory.edu Division of Endocrinology Grady Memorial Hospital

Med-Peds Continuity Clinic Baylor College of Medicine Anoop Agrawal, M.D. Other goals for insulin therapy Patients who no longer have -cell function require a Basal ...

Title: PowerPoint Presentation Author: Sufyan & Rasha Last modified by: Anthony Pomtree Created Date: 4/19/2002 4:45:18 AM Document presentation format

Diabetes Care 2000;23:S32-S42 Advanced carbohydrate counting * 8 12 6 10 RAA insulin Peakless Basal ( ~ 50 % ) * * * American Diabetes Association ...

master template

The Scottish electronic diabetes register and cancer registry and their linkage Sarah Wild, University of Edinburgh Thanks to David Brewster, Director of the Scottish ...

action et secretion de l insuline. insulines mises sur le marche. indications et non indications de l insuline dans le diabete de type 2. schemas d ...

Glucose Management. University of Colorado Hospital. Bridget Everhart, MSN, NP, CDE, CCRN ... Bridget Everhart Inpatient Diabetes Educator ...

in Type 2 Diabetes: Current and Future Directions Issues in the Management of Type 2 Diabetes Type 2: Deterioration of beta cells over time Increasing prevalence with ...

... estimate of how much glucose will be lowered by 1 unit of rapid-acting insulin ... Bolus insulin is given as rapid acting insulin. AIM Nomogram for MDI: Background ...

none

Increasing prevalence with increasing risk factors, eg, obesity ... 1997;349:97-51. White JR, et al. Postgrad Med. 1997;101:58-70. ...

Diabetes Mellitus Overview and Treatments Andrew P. Vogt Chemistry 6116 Diabetes Mellitus : a group of diseases characterized by high levels of blood glucose ...

Current Paradigms in the Rx of Type 2 DM A cost effective, practical approach to glycemic control C.R.Kannan, M.D. Consultant in Endocrinology, Southwest Medical ...